Americord Improves Cord Blood Collections - Journal of the American Society of Hematology

NEW YORK, March 31, 2014 /PRNewswire/ -- "Blood", a weekly medical journal published by the American Society of Hematology, has published an abstract on current research related to cord blood stem cell collection that was written by Americord's Executive Medical Director, Dr. Robert A. Dracker. Dr. Dracker's research, which is currently under way, is exploring a specific technology that could enable doctors to collect a dramatically larger volume of stem cells from cord blood available immediately after a baby is born. This technology is being pursued as a part of the development of Americord's proprietary CordAdvantage product.

CordAdvantage will harvest stem cells from cord blood from the placenta as well as the umbilical cord. Studies have demonstrated that placenta cord blood contains significantly more stem cells than umbilical cord blood alone does, which makes it a valuable source of stem cells. Having more stem cells available in the event they are needed for medical treatment is directly correlated to an increase in patients' survival rate.

"Blood" is the most cited peer-reviewed publication in the field of hematology and The American Society of Hematology is the world's largest professional society focused on the causes and treatments of blood disorders.

Dr. Dracker, a pediatrician, hematologist/oncologist, transfusion medicine specialist, and experienced blood and stem cell banking leader, is responsible for Americord's laboratory, collection and transport protocols and procedures, licensing and accreditation, establishing quality controls and advising the company with respect to scientific and medical matters. Prior to joining Americord in 2010, he was Executive Medical Director for ViaCord (now ViaCell) and Medical Director of Biocyte, the first cord blood company. He was also part of the Working Group on Cord Blood Stem Cell Guidelines for New York State and was an architect of the New York State cord blood banking licensing requirements, which are considered to be the gold standard of cord blood banking accreditations.

About Americord Registry

Americord Registry is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord's cord blood blog or website at cordadvantage.com for more information. You may also find Americord on Facebook and follow the company on Twitter.

Contact:
Andrew Flook
Americord Registry
866-503-6005
[email protected]

SOURCE Americord Registry

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED